Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고성호 | - |
dc.date.accessioned | 2019-12-08T04:59:33Z | - |
dc.date.available | 2019-12-08T04:59:33Z | - |
dc.date.issued | 2018-05 | - |
dc.identifier.citation | JOURNAL OF STROKE, v. 20, no. 2, page. 258-267 | en_US |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.issn | 2287-6405 | - |
dc.identifier.uri | https://www.j-stroke.org/journal/view.php?doi=10.5853/jos.2017.02712 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/118791 | - |
dc.description.abstract | Background and Purpose The pathophysiology of post-stroke depression (PSD) is complex and may differ according to an individual's mood immediately after stroke. Here, we compared the therapeutic response and clinical characteristics of PSD at a later stage between patients with and without depression immediately after stroke.Methods This study involved a post hoc analysis of data from EMOTION (ClinicalTrials.gov NCT01278498), a placebo-controlled, double-blind trial that examined the efficacy of escitalopram (10 mg/day) on PSD and other emotional disturbances among 478 patients with acute stroke. Participants were classified into the Baseline-Blue (patients with baseline depression at the time of randomization, defined per the Montgomery-Asberg Depression Rating Scale [MADRS]>= 8) or the Baseline-Pink groups (patients without baseline depression). We compared the efficacy of escitalopram and predictors of 3-month PSD (MADRS >=) between these groups.Results There were 203 Baseline-Pink and 275 Baseline-Blue patients. The efficacy of escitalopram in reducing PSD risk was more pronounced in the Baseline-Pink than in the Baseline-Blue group (P for interaction=0.058). Several risk factors differentially affected PSD development based on the presence of baseline depression (P for interaction <0.10). Cognitive dysfunction was an independent predictor of PSD in the Baseline-Blue, but not in the Baseline-Pink group, whereas the non-use of escitalopram and being female were more strongly associated with PSD in the Baseline-Pink group.Conclusions Responses to escitalopram and predictors of PSD 3 months following stroke differed based on the presence of baseline depression. Our data suggest that PSD pathophysiology is heterogeneous; therefore, different therapeutic strategies may be needed to prevent PSD emergence following stroke. | en_US |
dc.description.sponsorship | This study was supported by the Ministry for Health, Welfare, and Family Affairs, Republic of Korea (HI14C1985). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | KOREAN STROKE SOC | en_US |
dc.subject | Depression | en_US |
dc.subject | Stroke | en_US |
dc.subject | Escitalopram | en_US |
dc.subject | Anger | en_US |
dc.subject | Emotional incontinence | en_US |
dc.title | Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 20 | - |
dc.identifier.doi | 10.5853/jos.2017.02712 | - |
dc.relation.page | 258-258 | - |
dc.relation.journal | JOURNAL OF STROKE | - |
dc.contributor.googleauthor | Lee, Eun-Jae | - |
dc.contributor.googleauthor | Kim, Jong S. | - |
dc.contributor.googleauthor | Chang, Dae-Il | - |
dc.contributor.googleauthor | Park, Jong-Ho | - |
dc.contributor.googleauthor | Ahn, Seong Hwan | - |
dc.contributor.googleauthor | Cha, Jae-Kwan | - |
dc.contributor.googleauthor | Heo, Ji Hoe | - |
dc.contributor.googleauthor | Sohn, Sung-Il | - |
dc.contributor.googleauthor | Lee, Byung-Chul | - |
dc.contributor.googleauthor | Koh, Seong-Ho | - |
dc.relation.code | 2018005246 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | ksh213 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.